Growth Hormone Secretagogues: GHRH, Ghrelin, and the GH Axis
Map the signals behind growth hormone release, distinguish GHRH from ghrelin-receptor strategies, and interpret hormone measurements without turning them into broad outcome claims.
| Research focus | Signals regulating pituitary growth hormone release |
|---|---|
| GHRH strategy | Growth hormone-releasing hormone receptor |
| Ghrelin strategy | Growth hormone secretagogue receptor |
| Inhibitory signal | Somatostatin |
| Readout distinction | GH concentration, secretion pattern, and IGF-I are different measurements |
| Hero product | Ipamorelin |
Growth hormone secretagogues are research tools that stimulate growth hormone release. They do not all act at the same receptor. GHRH-related compounds and ghrelin-receptor agonists enter the system through different signals, even when an experiment measures GH as the shared endpoint.
The growth-hormone axis also includes inhibitory signals, changing secretion patterns, and downstream responses. Understanding that network makes it easier to interpret a hormone result without treating it as proof of a broader tissue or functional outcome.
Origin story: more than one route to GH release
Research into inhibitory control helped establish that GH release is actively regulated. Brazeau and colleagues isolated a hypothalamic peptide that inhibited GH secretion in experimental systems. That peptide became known as somatostatin (Brazeau et al., 1973).
Ghrelin supplied another part of the story. Kojima and colleagues identified an acylated peptide from stomach with GH-releasing activity. This connected a naturally occurring signal with the growth hormone secretagogue receptor research field (Kojima et al., 1999).
These findings describe distinct regulatory inputs. A framework that includes both stimulation and inhibition is more useful than imagining one switch that simply turns GH on. The observed response depends on the biological system and the question being measured.
How GHRH and ghrelin pathways work
GHRH-related materials act through the GHRH receptor strategy. The CJC-1295 development work investigated a modified GHRH-related construct and its GH and IGF-I responses. Ghrelin-related secretagogue research concerns a different receptor entry point (Jetté et al., 2005; Teichman et al., 2006; Kojima et al., 1999).
Ipamorelin illustrates the latter research area. Its discovery study investigated a synthetic pentapeptide with GH-releasing activity and compared its hormone-response profile with other secretagogues in laboratory and animal models (Raun et al., 1998).
Keep three measurements separate. GH concentration is a level detected at a particular time. A secretion pattern describes how release varies across observations. IGF-I is a downstream measurement with its own interpretation. None is a substitute for all the others.
This distinction matters when comparing studies. A larger single measurement may reflect different sampling rather than a larger integrated response. A downstream change may persist differently from the original GH signal. Define the endpoint before comparing numbers.
Key studies: compare pathway, model, and endpoint
| Research example | System | Question addressed | Limit |
|---|---|---|---|
| Somatostatin discovery | Hypothalamic material and experimental GH-secretion systems | Can a hypothalamic peptide inhibit release? | Not a complete map of every regulatory input |
| Ghrelin discovery | Peptide identification and functional experiments | Which natural ligand has GH-releasing activity? | Does not establish every downstream outcome |
| Ipamorelin discovery | Laboratory assays and animal models | How selective is the measured hormone response? | Model-specific selectivity |
| CJC-1295 study | Healthy adults | What GH and IGF-I responses follow the studied construct? | Construct-specific human pharmacology |
The selectivity claim for ipamorelin has a defined source. In the swine comparison, its ACTH and cortisol responses differed from those of the older comparator secretagogues under the tested conditions. That supports a specific comparison, not an assurance that every other effect is absent (Raun et al., 1998).
The human CJC-1295 findings concern the long-acting construct studied. They should not automatically be copied onto no-DAC material or another GHRH-related peptide. The DAC versus no-DAC comparison explains that identity boundary (Teichman et al., 2006).
For a combined-pathway experiment, evidence of interaction requires a design that distinguishes each input from the combination. Two materials affecting the same output do not automatically establish synergy, equivalent exposure, or a useful functional result together.
The secretagogue comparison develops the difference between potency, maximum response, and hormone selectivity. Those are separate questions even when all curves involve GH.
Weak spots: what we don’t know
A GH or IGF-I change does not by itself establish improved tissue function, performance, or a long-term outcome. Those claims need studies that actually measure the relevant endpoint in an appropriate model.
Also avoid assigning a universal receptor ranking from studies with different species, sampling, or materials. A comparison needs enough shared context to make the numerical difference meaningful.
As of November 5, 2026, ipamorelin and CJC-1295 are not FDA-approved human medicines. FDA identifies limited clinical information and safety concerns for these materials. Its compounding page keeps ipamorelin acetate in 503B category 2, while CJC-1295 moved to its withdrawn-nominations list in April 2026. An early endocrine response is not a substitute for that missing evidence (FDA, 2026).
Biological timing and laboratory stability remain separate too. A prolonged hormone response does not establish how long a reconstituted stock remains intact. Keep the material’s preparation and storage evidence independent of the endocrine explanation.
Handling secretagogue research materials in the lab
Record each material’s identity, construct, lot, content basis, and vehicle. Link those details to the assay model, sampling interval, and readout. This prevents a hormone result from becoming detached from the preparation that produced it.
For concentration math, a nominal 10 mg ipamorelin sample recovered at a final volume of 2 mL gives 5 mg/mL, or 5,000 mcg/mL. A 0.10 mL analytical aliquot contains a nominal 500 mcg.
The number describes mass transferred, not a predicted hormone response. A receptor experiment using molar concentration needs the appropriate molecular weight and content basis. Different materials should not be treated as equivalent because their vial labels show equal mass.
Consult the reconstitution guide and calculator for arithmetic. Solvent compatibility, storage, and biological activity still require material-specific evidence.
Growth hormone secretagogues FAQ
Are GHRH and ghrelin the same signal?
No. They represent different receptor strategies involved in GH-release research.
Does a GH increase prove a functional benefit?
No. A functional outcome requires its own appropriate measurement.
Does selectivity mean no other effects are possible?
No. Selectivity describes a defined comparison under tested conditions.
What is Hero Ipamorelin?
Hero Ipamorelin is the catalog’s ipamorelin research material, listed as a 10 mg vial. Evaluate its documentation separately from studies of native ghrelin or other secretagogues.
References
- Brazeau P, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-79. Source.
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660. Source.
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. Source.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. Source.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Source.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. Accessed November 5, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.